Zydus Lifesciences Limited (ZYDUSLIFE.BO)
INR 859.55
(2.64%)
INR 859.55
(2.64%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 251 Million INR | -100.0% |
| 2023 | 198 Million INR | -94.76% |
| 2022 | 3.78 Billion INR | -39.45% |
| 2021 | 6.24 Billion INR | -80.66% |
| 2020 | 32.29 Billion INR | -18.24% |
| 2019 | 39.49 Billion INR | 54.58% |
| 2018 | 25.55 Billion INR | 3.51% |
| 2017 | 24.68 Billion INR | 175.37% |
| 2016 | 8.96 Billion INR | -22.08% |
| 2015 | 11.5 Billion INR | -15.55% |
| 2014 | 13.62 Billion INR | -4.47% |
| 2013 | 14.26 Billion INR | 7.84% |
| 2012 | 13.22 Billion INR | 73.33% |
| 2011 | 7.62 Billion INR | -30.04% |
| 2010 | 10.9 Billion INR | -13.95% |
| 2009 | 12.67 Billion INR | 51.28% |
| 2008 | 8.37 Billion INR | 84.72% |
| 2007 | 4.53 Billion INR | 2.32% |
| 2006 | 4.43 Billion INR | 15.6% |
| 2005 | 3.83 Billion INR | -12.39% |
| 2004 | 4.37 Billion INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 FY | 251 Million INR | 26.77% |
| 2024 Q1 | - INR | -100.0% |
| 2024 Q4 | 251 Million INR | 0.0% |
| 2024 Q3 | - INR | -100.0% |
| 2024 Q2 | 307 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 198 Million INR | -94.76% |
| 2023 Q4 | 198 Million INR | 0.0% |
| 2023 Q2 | 3.08 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 3.78 Billion INR | 0.0% |
| 2022 FY | 3.78 Billion INR | -39.45% |
| 2022 Q2 | 4.64 Billion INR | 0.0% |
| 2021 Q2 | 15.01 Billion INR | 0.0% |
| 2021 Q4 | 6.24 Billion INR | 0.0% |
| 2021 FY | 6.24 Billion INR | -80.66% |
| 2020 Q4 | 32.29 Billion INR | 0.0% |
| 2020 FY | 32.29 Billion INR | -18.24% |
| 2020 Q2 | 37.73 Billion INR | 0.0% |
| 2019 Q2 | 27.87 Billion INR | 0.0% |
| 2019 FY | 39.49 Billion INR | 54.58% |
| 2019 Q4 | 39.49 Billion INR | 0.0% |
| 2018 Q2 | 27.14 Billion INR | 0.0% |
| 2018 Q4 | 25.55 Billion INR | 0.0% |
| 2018 FY | 25.55 Billion INR | 3.51% |
| 2017 Q2 | 9.68 Billion INR | 0.0% |
| 2017 FY | 24.68 Billion INR | 175.37% |
| 2017 Q4 | 24.68 Billion INR | 0.0% |
| 2016 Q4 | 8.96 Billion INR | 0.0% |
| 2016 FY | 8.96 Billion INR | -22.08% |
| 2016 Q2 | 10.85 Billion INR | 0.0% |
| 2015 Q2 | 11.93 Billion INR | 0.0% |
| 2015 Q4 | 11.5 Billion INR | 0.0% |
| 2015 FY | 11.5 Billion INR | -15.55% |
| 2014 Q4 | 13.62 Billion INR | 0.0% |
| 2014 Q2 | 15.64 Billion INR | 0.0% |
| 2014 FY | 13.62 Billion INR | -4.47% |
| 2013 FY | 14.26 Billion INR | 7.84% |
| 2013 Q2 | 12.19 Billion INR | 0.0% |
| 2013 Q4 | 14.26 Billion INR | 0.0% |
| 2012 Q4 | 13.22 Billion INR | 0.0% |
| 2012 FY | 13.22 Billion INR | 73.33% |
| 2011 FY | 7.62 Billion INR | -30.04% |
| 2010 FY | 10.9 Billion INR | -13.95% |
| 2009 FY | 12.67 Billion INR | 51.28% |
| 2008 FY | 8.37 Billion INR | 84.72% |
| 2007 FY | 4.53 Billion INR | 2.32% |
| 2006 FY | 4.43 Billion INR | 15.6% |
| 2005 FY | 3.83 Billion INR | -12.39% |
| 2004 FY | 4.37 Billion INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 60.083% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 98.824% |
| Glenmark Life Sciences Limited | 147.61 Million INR | -70.043% |
| Granules India Limited | 689.71 Million INR | 63.608% |
| Indoco Remedies Limited | 3.51 Billion INR | 92.864% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 235.2 Million INR | -6.718% |
| Alkem Laboratories Limited | 400 Million INR | 37.25% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -6940.673% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -801.71% |
| Bajaj HealthCare Limited | 650.34 Million INR | 61.405% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 29.479% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 95.81% |
| Eris Lifesciences Limited | 6.54 Billion INR | 96.165% |
| FDC Limited | 2.46 Million INR | -10078.427% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 83.453% |
| Gufic Biosciences Limited | 1.53 Billion INR | 83.697% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -124.858% |
| Ipca Laboratories Limited | 5.8 Billion INR | 95.675% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -232.142% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 86.322% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 97.083% |
| Lupin Limited | 1.55 Billion INR | 83.836% |
| Mankind Pharma Limited | 248.67 Million INR | -0.934% |
| Medicamen Biotech Limited | 12.55 Million INR | -1899.204% |
| Medico Remedies Limited | 8.67 Million INR | -2794.373% |
| Megasoft Limited | 1.35 Billion INR | 81.504% |
| NATCO Pharma Limited | 53 Million INR | -373.585% |
| Piramal Pharma Limited | 24.83 Billion INR | 98.989% |
| RPG Life Sciences Limited | -30.3 Million INR | 928.383% |
| Sigachi Industries Limited | 265.79 Million INR | 5.567% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -1787.218% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | -18.198% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 20690.648% |
| Unichem Laboratories Limited | 382.22 Million INR | 34.331% |
| Wanbury Limited | 820 Million INR | 69.39% |
| Windlas Biotech Limited | 20.18 Million INR | -1143.806% |
| ZIM Laboratories Limited | 356 Million INR | 29.496% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -135.46% |
| Divi's Laboratories Limited | 20 Million INR | -1155.0% |
| Hester Biosciences Limited | 1.81 Billion INR | 86.192% |
| Procter & Gamble Health Limited | 68.8 Million INR | -264.826% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -1696.964% |
| Bal Pharma Limited | 363.82 Million INR | 31.011% |
| Strides Pharma Science Limited | 6.71 Billion INR | 96.262% |
| Venus Remedies Limited | 386.8 Million INR | 35.109% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -62650.0% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 82.111% |
| Shilpa Medicare Limited | 5.6 Billion INR | 95.519% |
| Aarti Drugs Limited | 2.75 Billion INR | 90.884% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 97.514% |
| Valiant Laboratories Limited | 746.63 Million INR | 66.382% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | -6.176% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 76.283% |
| Themis Medicare Limited | 267.74 Million INR | 6.252% |
| Hikal Limited | 4.22 Billion INR | 94.064% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 98.435% |
| Sequent Scientific Limited | 1.42 Billion INR | 82.413% |
| Novartis India Limited | 50.7 Million INR | -395.069% |
| Wockhardt Limited | 8.91 Billion INR | 97.183% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.207% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 449.2 Million INR | 44.124% |
| Morepen Laboratories Limited | 33.64 Million INR | -646.136% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | -87.957% |